Atai stocks.

Atai Life Sciences (NASDAQ: ATAI) just announced it has laid off roughly 30% of its staff. Shares are rising today, but it’s been a very difficult year for this penny stock. After declining more ...

Atai stocks. Things To Know About Atai stocks.

Get the latest Atai Life Sciences N.V. (ATAI) stock news and headlines to help you in your trading and investing decisions.2 days ago · ATAI Life Sciences Stock (NASDAQ: ATAI) stock price, news, charts, stock research, profile. Nov 21, 2023 · The Trade: Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares. The insider ... As of last trade ATAI Life Sciences NV (ATAI:NMQ) traded at 1.10, 4.76% above its 52-week low of 1.05, set on Oct 27, 2023. Data delayed at least 15 minutes, as of Nov 30 2023 18:35 GMT. Latest ATAI Life Sciences NV (ATAI:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and …

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Insider Trading.ATAI Life Sciences NV (ATAI) stock is trading at $3.05 as of 3:20 PM on Thursday, Dec 15, a drop of -$0.05, or -1.77% from the previous closing price of $3.10. The stock has traded between $2.98 and $3.10 so far today. Volume today is low. So far 597,235 shares have traded compared to average volume of 1,159,249 shares. Click Here to get the ...At Compass’ current market cap of ~$1.1 billion, ATAI has a $200 – 300 million stake in the company. This gives ATAI’s valuation a sort of floor dependent on Compass’ ultimate market cap. It will be just as important for Compass to succeed over the coming months as it will for ATAI’s portfolio companies to perform.Web

Atai Life Sciences N.V. (NASDAQ: ATAI) is a Germany-based biopharma company focusing on the development of psychedelic drugs. It is placed second on our list of 10 best psychedelic stocks to buy now.Nov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.

On January 6, Atai announced that a highly anticipated trial of a ketamine-based depression treatment failed to meet its goals. The news sent Atai's stock tumbling by about a third, deepening the ...atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation ...Stock analysis for ATAI Life Sciences NV (ATAI:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.ATAI Life Sciences-stock ATAI Life Sciences N.V. Registered Shs Stock , ATAI 1.14 +0.04 +3.64% After-market 04:50:40 PM EDT 11/24/2023 NAS Add to …

Even in a speculative industry, I believe the stock is undervalued by these few facts alone. ATAI holds: 450M cash and cash equivalents; 20% equity stake in CMPS (750M mktcp - 150M worth at current prices); and ATAI has a vast ip pipeline that includes 9 lead compounds. Curious as to the community’s thoughts here!

23 thg 4, 2021 ... Founded in 2018, ATAI Life Sciences is a German biotech startup that has raised $304 million in disclosed funding to build a holding company ...

According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price.Looking for the best stocks under $2 to buy in 2023? MarketBeat has identified 25 low-priced stocks that you should consider for your portfolio. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. ... #12 - Atai Life Sciences NASDAQ:ATAI Stock Price: $1.12 (+$0.08) PE Ratio: ...WebATAI Stock Price Today by TradingView. Atai Life Sciences (NASDAQ: ATAI) is “a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments.” Like many companies on this list, they are working on treatments for mental health issues like ...Feb 9, 2023 · 1. ATAI Life Sciences. The financial services firm H.C. Wainwright & Co. recently issued a $20 price target on ATAI Life Sciences (ATAI 7.69%) stock. This 12-month price target implies an upside ... In May 2021, Atai purchased additional preferred stock of Neuronasal. As of the date, the company now holds a 56.5% equity ownership position in Neuronasal – a company focused on treating concussions and other forms of …Apr 20, 2023 · With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ... The latest Atari stock prices, stock quotes, news, and PONGF history to help you invest and trade smarter.

As of last trade ATAI Life Sciences NV (ATAI:NMQ) traded at 1.10, 4.76% above its 52-week low of 1.05, set on Oct 27, 2023. Data delayed at least 15 minutes, as of Nov 30 2023 18:35 GMT. Latest ATAI Life Sciences NV (ATAI:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and …atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN. Current and historical return on equity (ROE) values for Atai Life Sciences (ATAI) over the last 10 years. Return on equity can be defined as the amount of net income ...A community of stock market investors in the legal psychedelics sector. Global drug policy is changing, and psychedelic therapies are next in line for decriminalization, research, and sale. ... Florian Brand and Srinivas Rao from ATAI Life Sciences-- 03/24/2023. Ronan Levy from Field Trip Health-- 11/22/2022.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Validation of atai's operating model and ability to capture value: IPO of COMPASS Pathways in 2020 and licensing deal between Otsuka and atai subsidiary Perception Neuroscience in 2021 Strong cash position of approx. $273M (as of December 31 st , 2022) and access to up to an additional $160m from term loan facility with Hercules 2 lead to ...After declining more than 62% over the past six months, ATAI stock needs a positive catalyst to turn things around. This is likely part of the reason behind the Atai layoffs, which follow the company’s promise to implement a “company-wide cost optimization” initiative, a measure that hasn’t yet yielded the intended results.WebNov 14, 2023 · Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers:

The current price ATAI Life Sciences (ATAI) is trading at is $1.06, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular ChannelsThis stake is worth roughly $98M as of Tuesday, March 28, based on COMPASS Pathways’ closing price of $10.23/share on that day. You can find atai’s filed 10-K from last Friday here. With ...

On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until the 2024 annual meeting of the ...WebA high-level overview of Atari SA (PONGF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Validation of atai's operating model and ability to capture value: IPO of COMPASS Pathways in 2020 and licensing deal between Otsuka and atai subsidiary Perception Neuroscience in 2021 Strong cash position of approx. $273M (as of December 31 st , 2022) and access to up to an additional $160m from term loan facility with Hercules 2 lead to ...Atai Life Sciences N.V. (NASDAQ: ATAI) is a Germany-based biopharma company focusing on the development of psychedelic drugs. It is placed second on our list of 10 best psychedelic stocks to buy now.Jan 17, 2023 · Atai Life Sciences (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. In the first week of the new year, the stock plummeted when the failed results of ATAI's NYC-based subsidiary, Perception Neuroscience's Phase 2a study of proprietary R-ketamine PCN-101 on patients with ... ATAI Life Sciences N.V. Watch Set a price target alert Premarket Last Updated: Nov 15, 2023 8:18 a.m. EST Delayed quote $ 1.2900 0.04 2.79% Before Hours Volume: 2.23K …Nov 24, 2023 · Compare with up to 5 Stocks. On Friday 11/24/2023 the closing price of the ATAI Life Sciences N.V. Registered Shs share was $1.10 on NAS. Compared to the opening price on Friday 11/24/2023 on NAS ... On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until …

In May 2021, Atai purchased additional preferred stock of Neuronasal. As of the date, the company now holds a 56.5% equity ownership position in Neuronasal – a company focused on treating concussions and other forms of …

Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ...

atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN. Current and historical return on equity (ROE) values for Atai Life Sciences (ATAI) over the last 10 years. Return on equity can be defined as the amount of net income ...Mar 6, 2023 · In January, Atai's majority-owned unit Perception Neuroscience's therapy PCN-101 (R-ketamine) did not meet the main goal of a phase 2a trial in treatment-resistant depression which sent the stock ... intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 11/24/2023 the closing price of the ATAI Life Sciences N.V. Registered Shs share was $1.10...ATAI stock, a health technology company in the pharmaceutical industry, had a mixed performance on November 21, 2023, according to data from CNN Money. The stock opened at $1.10 and traded within a narrow range of $1.09 to $1.11. The trading volume was relatively low at 18,798 shares. ATAI has a market capitalization of $182.6 million.ATAI Life Sciences. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01 ... intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 11/24/2023 the closing price of the ATAI Life Sciences N.V. Registered Shs share was $1.10...atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN. Current and historical return on equity (ROE) values for Atai Life Sciences (ATAI) over the last 10 years. Return on equity can be defined as the amount of net income ...Mar 6, 2023 · In January, Atai's majority-owned unit Perception Neuroscience's therapy PCN-101 (R-ketamine) did not meet the main goal of a phase 2a trial in treatment-resistant depression which sent the stock ... Jan 17, 2023 · Atai Life Sciences (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. In the first week of the new year, the stock plummeted when the failed results of ATAI's NYC-based subsidiary, Perception Neuroscience's Phase 2a study of proprietary R-ketamine PCN-101 on patients with ... atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditionsContinued ...In May 2021, Atai purchased additional preferred stock of Neuronasal. As of the date, the company now holds a 56.5% equity ownership position in Neuronasal – a company focused on treating concussions and other forms of …

Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.RPHM. Reneo Pharmaceuticals Inc. 6.04. +0.10. +1.68%. Get ATAI Life Sciences NV (ATAI:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...Instagram:https://instagram. dividends johnson and johnsonjewelry investmentdoes primexbt require kycnee stock forecast Atai Capital experienced a decline of 5.8% in the third quarter, bringing our year-to-date (YTD) returns to 6.5% net of all fees. This compares to a 13.1% total return for the S&P 500 YTD and a 2. ...Atai Life Sciences Market Cap. Atai Life Sciences has a market cap or net worth of $180.95 million as of November 22, 2023. Its market cap has decreased by - ... can you day trade with fidelitycheapest futures commissions Discover historical prices for ATAI stock on Yahoo Finance. View daily, weekly or monthly format back to when Atai Life Sciences N.V. stock was issued. acura lsx On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until …With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you …